Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Deal closed
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction. Maxim Group LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.
Wonder if we hear about the intended use of funds this week?
A PR about the start of study should not do much other than show progress. However, we should see the results of the bioequivalencey study for eli-202 and the life tree results this fall. Eli-202 should pass since ELTP has already shown proof of concept with ELI 200 and 201. IMO The life tree results are the big risk left between now and FDA approval. If they come back positive our share price should react favorably. Also, IMO that is when ELTP will look to make a deal with a manufacturing and distribution partner. That deal would be very favorable at that point because Elite has already taken on the majority of the risk as well as the cost of trials and FDA approval. The path Dr. Hakim is taking with the LPC deal and not signing with a partner seems to be the one of most profitability once these drugs hit the market.
To maintain our market cap after adding ~22 million shares we should sit around .70.
Are they only testing for crushing the drug? I would think they would also want to test snorting.
You can always call them, but if you use standard service than you should see it updated Monday. Your money is safe though.
The 20mil shares should come from the treasury. It would not be an open market transaction.
I keep think about the explanation for raising additional capital that we are going to get Friday or Monday after the deal closes. IMO we will see the start of a new trial for head and neck or breast cancer. It makes the most since and would be something Punit would get excited about. ONCS has also proven the concept with the phase 2a melanoma. That would make this a good time to increase the pipeline to other cancers.
R/S tonight. GLTA.
I bet we see a bullish PR this week or Monday. I just wonder what it will be. I would love to see partnership for the phase 2b.
There is overreaction and a lot of the short term traders will leave. Also to maintain the market cap with the new shares we should sit right above .7.
Philospher 42
With the additional 22.53 shares outstanding we should sit on .7 to maintain the current market cap of about 165million
Bring on the breast/head and neck trials.
I do not know about a huge upward movement, but I see what you are talking about. It wouldn't surprise me to end about even today.
ELTP is trading in a very tight range with low volume. I have not seen ELTP with this little volatility this year. Most of the flippers and sellers have now left and we are sitting on a nice base. In the next two months I would expect earnings and completion of bioequivalencey for Eli-202 to offer nice catalyst for the next move up. Many other things could be released over the next two months, but these should be the big movers.
All IMO
GLTA
I posted this a while ago. It offers good insight to why our price is moving this way, and why it usually takes ONCS a few days after news to begin a move up.
http://shockertrades.blogspot.com/2011/05/market-maker-speaks-out-ways-of-market.html
ONCS offers a limited short term downside and explosive future potential. It is the perfect stock to hold down and accumulate. When the buy orders start rushing in they will have the shares to sell for a nice profit. This offers a great opportunity for all investors that are able to see it and act upon it.
I haven't seen too much media coverage but I didn't hear anyone mentioned by name directly. ASCO recognized their break through and invited them to be a feature presenter. Recognition from your peers says more about their progress than being interviewed on CNBC for a few min.
They are talking about immunotherapy from ASCO on the Today Show. This will be the standard of care before too long.
This is on the today show right now.
Any idea of the duration of the trial?
As long as they are trying to get better than they were yesterday I am happy.
The LD Micro 4th Invitational looks like a great opportunity for ONCS to get new investor attention.
I appreciate the thorough response. I've been in oncs for awhile and looking to get into INO. The R/S and dilution hitting the pps created an awesome time to jump in. The perceived bad news is out of the way and good things should be coming.
I appreciate the thorough response. I've been in ONCS for a while and was looking to get into INO. The R/S and dilution hitting the pps created an awesome buying opportunity. The perceived bad news is out of the way. Only good things coming.
When are phase 2 results expected?
What is the benefit today of being a feature presenter?
I would just like to see the .9s again.
Its biotech. Results are everything for each company. Some good ones should be here soon!
Other than the trial results does anyone think other news will come out? Making one of the smallest companies at ASCO a feature presenter seems like an odd move unless they have something unexpected. Maybe the unknown data in the trial was out of this world. Or we could get partnership news that morning, and the added discussion time could be used to explain how phase 2b trials would proceed with the partners drug. I just keep thinking about the possibilities. Even if it’s only the expected solid results it should be fun, but I cannot help thinking there is something more to it.
Awesome. Thanks for the link.
How did you come up with 50%? It would seem that a higher pps would allow institutions to purchase shares that have restrictions against stocks with pps below $5. Immuno-Oncology is the big buzz in pharma and INO could be a big time player in this field. People realize this, and the pps should climb from here. I had been looking for a good buying opportunity to get into INO and the R/S offered one. I think we have seen the markets reaction to the split, and this is a good opportunity before INO's pipeline becomes further developed and institutions get into the game.
I'm curious to see if we see a good amount of shorts covering at the end of the day today. I would love to see ONCS get near .80 heading into the weekend.
I would think this summer so they can prep for the phase 2b trial.
Did he mention anything about the use of MK-3475 in the phase 2B trial?
You might as well. You tend to complain when the opposite happens.